Gene · 8744
Papers3,166
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
181 to 200 of 3,166
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Oncolytic Virotherapy: A New Paradigm in Cancer Immunotherapy. | Int J Mol Sci | 2024 | 38256250 | PubTator, text mining | PubMed |
| Single-cell landscape identifies the immunophenotypes and microenvironments of HBV-positive and HBV-negative liver cancer. | Hepatol Commun | 2024 | 38251896 | PubTator, text mining | PubMed |
| Macro CD5L+ deteriorates CD8+T cells exhaustion and impairs combination of Gemcitabine-Oxaliplatin-Lenvatinib-anti-PD1 therapy in intrahepatic cholangiocarcinoma. | Nat Commun | 2024 | 38245530 | PubTator, text mining | PubMed |
| The roles and molecular mechanisms of non-coding RNA in cancer metabolic reprogramming. | Cancer Cell Int | 2024 | 38238756 | PubTator, text mining | PubMed |
| BTLA biology in cancer: from bench discoveries to clinical potentials. | Biomark Res | 2024 | 38233898 | PubTator, text mining | PubMed |
| Zinc Transporters Serve as Prognostic Predictors and their Expression Correlates with Immune Cell Infiltration in Specific Cancer: A Pan-cancer Analysis. | J Cancer | 2024 | 38230214 | PubTator, text mining | PubMed |
| Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma. | Sci Rep | 2024 | 38228729 | PubTator, text mining | PubMed |
| Prediction of immune infiltration and prognosis for patients with cholangiocarcinoma based on a cuproptosis-related lncRNA signature. | Heliyon | 2024 | 38226253 | PubTator, text mining | PubMed |
| Targeted screening of inflammatory mediators in spontaneous degenerative disc disease in dogs reveals an upregulation of the tumor necrosis superfamily. | JOR Spine | 2024 | 38222814 | PubTator, text mining | PubMed |
| T proliferating cells derived autophagy signature associated with prognosis and immunotherapy resistance in a pan-cancer analysis. | iScience | 2024 | 38222108 | PubTator, text mining | PubMed |
| Development and validation of epigenetic modification-related signals for the diagnosis and prognosis of colorectal cancer. | BMC Genomics | 2024 | 38212708 | PubTator, text mining | PubMed |
| HBV infection effects prognosis and activates the immune response in intrahepatic cholangiocarcinoma. | Hepatol Commun | 2024 | 38206204 | PubTator, text mining | PubMed |
| PRKCSH contributes to TNFSF resistance by extending IGF1R half-life and activation in lung cancer. | Exp Mol Med | 2024 | 38200153 | PubTator, text mining | PubMed |
| cGAS-STING, inflammasomes and pyroptosis: an overview of crosstalk mechanism of activation and regulation. | Cell Commun Signal | 2024 | 38195584 | PubTator, text mining | PubMed |
| Natural killer cells drive 4-1BBL positive uveal melanoma towards EMT and metastatic disease. | J Exp Clin Cancer Res | 2024 | 38191418 | PubTator, text mining | PubMed |
| Impact of tissue penetration and albumin binding on design of T cell targeted bispecific agents. | Neoplasia | 2024 | 38183712 | PubTator, text mining | PubMed |
| Single-cell RNA-seq reveals the metabolic status of immune cells response to immunotherapy in triple-negative breast cancer. | Comput Biol Med | 2024 | 38183706 | PubTator, text mining | PubMed |
| Mechanisms and effects of NLRP3 in digestive cancers. | Cell Death Discov | 2024 | 38182564 | PubTator, text mining | PubMed |
| Integrated bioinformatics analysis and experimental validation identified CDCA families as prognostic biomarkers and sensitive indicators for rapamycin treatment of glioma. | PLoS One | 2024 | 38181024 | PubTator, text mining | PubMed |
| Identification and prognostic biomarkers among ZDHHC4/12/18/24, and APT2 in lung adenocarcinoma. | Sci Rep | 2024 | 38177255 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8744/papers?page=10